Research Roundup: Alzheimer’s; Cancer; Covid; Weight-Loss Pill
Each week, KHN compiles a selection of recently released health policy studies and briefs.
ScienceDaily:
Researchers Identify New Gene Mutation That Alters Alzheimer's Disease Risk
A groundbreaking study led by experts from Indiana University School of Medicine has shed new light on the genetic underpinnings of Alzheimer's disease. (Indiana University School of Medicine, 9/6)
CIDRAP:
Cancer Diagnoses Fell Early In COVID Pandemic, But Many Types Eventually Climbed Again
In April 2020, diagnoses fell 23% for any type of cancer, 46% for breast, 35% for colon, 47% for rectal, 50% for head and neck, 65% for melanoma, and 33% for endocrine cancer and rose 12% for blood cancer and 8% for cancers with an unknown primary site. (Van Beusekom, 9/6)
CIDRAP:
Stress Over Family Members' COVID Hospitalization Lessens After 1 Year, Survey Finds
A new research letter in JAMA notes that, compared with 3 months after patient intensive care unit (ICU) hospitalization for acute respiratory distress syndrome (ARDS) caused by COVID-19, at 1 year family members had lower levels of post-traumatic stress disorder (PTSD), anxiety, or depression. Moreover, ARDS caused by COVID-19 compared to ARDS caused by other illnesses was not associated with any greater psychological distress among family members. (Soucheray, 9/5)
New England Journal of Medicine:
Daily Oral GLP-1 Receptor Agonist Orforglipron For Adults With Obesity
Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. (Wharton, et al, 9/7)
